课题基金 / 基金详情

Intravitreal bevacizumab for retinal conditions: real-world safety assessment

Intravitreal bevacizumab for retinal conditions: real-world safety assessment
玻璃体内注射贝伐单抗治疗视网膜疾病：真实世界安全性评估
批准号：
349640
负责人：
Bernatsky Sasha R
金额：
$7.29万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Miscellaneous Programs
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-05-01 至 2017-05-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=349640&lang=en
关键词：
Safety Assessment

项目摘要

项目成果

Bernatsky Sasha R的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Age-related macular degeneration (AMD) is the leading cause of blindness among Americans over 40 years of age and affects more than 2 million Canadians over the age of 501. The advent and widespread use of anti-vascular endothelial growth factor (anti-VEG
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Environmental factors and risk of autoimmune rheumatic disease incidence and serology
Air pollution and systemic autoimmune rheumatic diseases
Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs
Hydroxychloroquine in systemic lupus
海外基金